This latest recognition follows OXB’s previous success at the CDMO Leadership Awards in 2025, when the Company was named a winner in the ‘Cell & Gene Therapy – Global’ category, and later recognised ...

Oxford-based cell and gene therapy firm OXB has reported significant growth in its latest preliminary results – a trend it expects to continue throughout the current financial year. The business ...

SYDNEY, March 18, 2026 (GLOBE NEWSWIRE)-- Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), ...

Oxford Innotech Bhd managing director Ng Thean Gin. PETALING JAYA: Oxford Innotech Bhd (OXB) has accepted a second letter of award from the Singapore office of an Australia-based data centre (DC) and ...

PETALING JAYA: Oxford Innotech Bhd (OXB) has accepted a second letter of award from the Singapore office of an Australia-based data centre and computer room infrastructure specialist to supply ...

OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giant’s CAR-T programs. The newly expanded ...

Initially, Handbrake became popular with the Mac OS and its approach was limited to those possessing expensive Apple devices. Today this open-source converter is used widely across Mac OS, Windows, ...

Live webcasts and recordings of presentations, where available, will be accessible under ‘Results, Reports, Presentations & Webcasts’ in the Investor Relations section of OXB’s website at www.oxb.com.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A large manufacturing facility ...

OXB acquires Resilience's site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB's previously announced strategy to add US GMP capacity across ...

Investing.com -- Oxford Biomedica has purchased a manufacturing site in Durham, North Carolina for £3.4 million, significantly accelerating its US expansion plans. The site, which cost approximately ...

Biopharmaceutical contract manufacturer OXB (OXB) has raised £60mn through a placing and subscription of nearly 14mn shares at 431p, a 1.9 per cent discount to the 14 August closing price. The deal, ...